Jefferies Financial Group reissued a 'buy' rating on Monte Rosa Therapeutics, whose stock trades on the Nasdaq exchange.

The entities involved

• Monte Rosa Therapeutics →

  biotechnology company

  Nothing else this week.

• Jefferies Financial Group →

  American financial services company

  • Jefferies Financial Group began coverage, Morgan Stanley set a high price target, and Keefe, Bruyette & Woods increased price objectives, with MarketBeat reporting the average stock rating.00:06
  • ExxonMobil is facing institutional investment disclosure requirements as Jefferies and HSBC provide updated rating and price targets.Mon 15:59
• Nasdaq →

  American fully electronic stock exchange

  • Anthropic plans to list on Nasdaq, while market analysis suggests AI IPOs could redirect capital toward crypto assets like Bitcoin.Mon 23:25
  • Match Group, which owns Hinge and Tinder, declared a cash dividend while being listed on the Nasdaq stock exchange.Mon 23:01
• Nasdaq →

  American fully electronic stock exchange

  • MicroStrategy Inc utilized its at-the-market offering program to sell shares on Nasdaq, using proceeds from its holdings of BTC.Mon 22:19
  • United-Guardian began trading on the Nasdaq stock exchange.Mon 20:23

Related events

• Jefferies Financial Group reaffirmed a Buy rating on London Stock Exchange Group.Oct 23
• Jefferies Financial Group and Raymond James Financial reaffirmed buy ratings on Compass Pathways stock, which MarketBeat is tracking.Jul 20
• Financial firms, including Jefferies, RBC, and Wells Fargo, issued rating and price objective updates for Biogen.Oct 23
• Jefferies Financial Group cut the stock rating for Carlsberg Group to 'hold' on October 13, 2026.Oct 13
• Jefferies Financial Group restated a buy rating on PPHE Hotel Group on July 1, 2026.Jul 3